AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

SynAct Pharma Board/Management Information 2024

Apr 23, 2024

3114_rns_2024-04-23_b188c661-3ccd-4857-9332-084d72c76150.pdf

Board/Management Information

Open in viewer

Opens in your device viewer

Changes in SynAct Pharma's Nomination Committee ahead of the 2024 Annual General Meeting

SynAct Pharma's Nomination Committee for the 2024 Annual General Meeting was announced in a press release on November 22, 2023. As a result of the appointment of new Board members, following a resolution by the Extra General Meeting on March 20, 2024, the composition of the Nomination Committee has changed. Henrik Stage replaces Anders Kronborg as representative for Goodwind Holding GmbH. Anders Kronborg will remain on the Nomination Committee in his capacity as Chairman of the Board of SynAct Pharma, replacing the previous Chairman of the Board in the Nomination Committee.

The Nomination Committee for the 2024 Annual General Meeting will thereafter consists of the following members:

Niels Ankerstjerne Sloth, Chairman of the Nomination Committee, appointed by Bioinvest Aps
Per Colleen, appointed by TomEnterprise Public Capital AB
Henrik Stage, appointed by Goodwind Holding GmbH
Anders Kronborg, Chairman of the Board of Directors

The Nomination Committee's proposed items will be presented in the notice convening the Annual General Meeting and on SynAct's web site. SynAct Pharma's Annual General Meeting 2024 will be held on Friday, May 31, 2024.

For further information, please contact: Björn Westberg CFO, SynAct Pharma AB

Phone: +46 73 394 09 53 Mail: [email protected]

About SynAct Pharma AB

SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity to help patients achieve immune balance and overcome their inflammation. For more information: www. synactpharma.com.

Attachments